Biotechnology

Dongcheng Biochem

Dongcheng Biochem released FY2026 Q1 earnings on April 27 Pre-Market (BJT), actual revenue CNY 626.37 M, actual EPS CNY 0.0405

Dongcheng Biochem FY2026 Q1 Earnings Release on April 28 Pre-Market BJT

Dongcheng Biochem released FY2025 Q4 earnings on March 25 After-Market (BJT), actual revenue CNY 697.99 M, actual EPS CNY 0.0563

Dongcheng Biochem released FY2025 earnings on March 25 After-Market (BJT), actual revenue CNY 2.741 B (forecast CNY 2.85 B), actual EPS CNY 0.2372 (forecast CNY 0.32)

Dongcheng Biochem to Release FY2025 Earnings on March 26 After-Market (BJT), Forecast Revenue CNY 2.85 B, EPS CNY 0.32

Dongcheng Biochem released FY2025 9-month earnings on October 28 After-Market BJT, actual revenue CNY 2.043 B, actual EPS CNY 0.1807

Dongcheng Biochem released FY2025 Q3 earnings on October 28 After-Market (BJT), actual revenue CNY 659.38 M, actual EPS CNY 0.0732

Dongcheng Biochem FY2025 Q3 Earnings Release on October 29 After-Market (BJT)

Dongcheng Biochem released FY2025 Semi-Annual Earnings on August 14 During-Market (BJT), Actual Revenue: CNY 1.384 B, Actual EPS: CNY 0.1074

Dongcheng Biochem released FY2025 Q2 earnings on August 14 During-Market (BJT), actual revenue CNY 696.78 M, actual EPS CNY 0.0774

Dongcheng Biochem to Release FY2025 Semi-Annual Earnings on August 15, 2025 (BJT)

East China Pharmaceutical Publishes International Patent Application and Increases R&D Expenditure

East China Pharmaceutical Subsidiary Receives GMP Certification and Adds a New Radiopharmaceutical Production Center

East China Pharmaceutical Obtains Patent for High Yield Fructose Chondroitin E. coli

East China Pharmaceutical Bluanchor completes Phase III clinical trial participant enrollment for Fluorine-18 SIRUIT peptide injection

East China Pharmaceutical Responds to Clinical Trial Progress of BNCT Drug

Anke Obtained Registration Certificate for Sodium Fluoride [18F] Injection

Dongcheng North's Injectable Hydrocortisone Succinate Sodium Passes Consistency Evaluation

 Dongcheng Pharmaceutical Plans to Acquire Minority Shareholder Equity in Subsidiary

Dongcheng Biochem released FY2025 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 686.93 M, actual EPS CNY 0.03

002675

江苏鼎泰药物研究(集团)股份有限公司

688488

Jiangsu Aidea Pharmaceutical plans to pursue an IPO in Hong Kong to facilitate its expansion into the US and European markets. The company, currently listed on the Shanghai Stock Exchange, views Hong Kong as a strategic entry point due to its flexible fundraising environment. With expectations for the Aids treatment sector to exceed 10 billion yuan by 2027, Jiangsu Aidea aims to develop competitive products and has initiated discussions with Hong Kong's drug regulator. The company recently announced a financing plan of 1.2 billion yuan, primarily for US clinical projects.

SCMP

Aidea Pharma

China’s Jiangsu Aidea eyes Hong Kong IPO as gateway to US, European Aids markets

According to the Zhitong Finance APP, Dongcheng Biochem announced that its subsidiary Yantai Lannacheng Biotechnology Co., Ltd. (referred to as "Lannacheng") has submitted the application materials for its initial public offering and listing on the main board of the Hong Kong Stock Exchange, which has been published on the Stock Exchange's website

Zhitong

Dongcheng Biochem's subsidiary Lanacheng has submitted an application for the issuance and listing of H shares

According to the Zhitong Finance APP, Dongcheng Biochem announced that its holding subsidiary Yantai LNC Biotechnology Co., Ltd. (referred to as "LNC") has received the clinical trial approval notice for the drug 225Ac-LNC1011 issued by the National Medical Products Administration of China, and will soon conduct clinical trials for prostate cancer

Dongcheng Biochem: 225Ac-LNC1011 injection has received clinical trial approval

Dongcheng Biochem announced that the company's supervisory board has approved the proposal for the spin-off of its subsidiary Yantai Lanna Cheng Biotechnology Co., Ltd. to be listed on the Main Board of the Hong Kong Stock Exchange. The initial issuance scale for Lanna is not to exceed 25% of the total expanded share capital immediately after the issuance, and grants the overall coordinator an over-allotment option of up to 15% of the aforementioned H share initial issuance scale. This spin-off listing plan needs to be submitted for approval at the company's shareholders' meeting

Dongcheng Biochem: Plans to spin off its subsidiary Lanacheng for listing on the main board of the Hong Kong Stock Exchange

Dongcheng Biochem's subsidiary LNC PHARMA PTE. LTD. has received FDA approval to conduct Phase I clinical trials for the 225Ac-LNC1011 injection. The FDA has completed the safety review of the drug and believes that clinical research for prostate cancer can continue. After receiving approval, the drug still needs to complete clinical trials and pass FDA review before it can be marketed in the United States

Dongcheng Biochem's subsidiary has received the drug clinical trial approval notice

Dongcheng Biochem announced that in the first half of 2025, operating revenue was 1.384 billion yuan, a year-on-year decrease of 2.60%. Net profit was 88.6525 million yuan, a year-on-year decrease of 20.70%

Dongcheng Biochem: Net profit of 88.6525 million yuan in the first half of 2025, a year-on-year decrease of 20.70%

According to the Zhitong Finance APP, Dongcheng Biochem announced that its wholly-owned subsidiary, Jiangxi Andike Pharmaceutical Co., Ltd. (referred to as "Jiangxi Andike"), has received the "Drug GMP Compliance Inspection Result Notification" issued by the Jiangxi Provincial Drug Administration, adding the Jiangxi Yichun Nuclear Medicine Production Center

Dongcheng Biochem: Jiangxi Yichun Nuclear Medicine Production Center Commences Operations

Dongcheng Biochem announced that its holding subsidiary Yantai Lanna Bio-Tech Co., Ltd. has completed the enrollment of all 488 subjects in the Phase III clinical trial of Fluorine-18 [18F] PSMA-617 injection. This drug is a radiopharmaceutical diagnostic agent targeting PSMA, suitable for PET imaging in prostate cancer patients, with high specificity and affinity

Dongcheng Biochem: The Phase III clinical trial of Fluorine [18F] Siretu Injection has completed the enrollment of all subjects

Dongcheng Biochem's wholly-owned subsidiary AndiKe recently received approval from the National Medical Products Administration, and the Sodium Fluoride [18F] Injection has passed the drug market authorization application, obtaining a drug registration certificate. This drug is a PET radiopharmaceutical that can effectively diagnose bone metastatic lesions, enhancing the company's product line and market competitiveness. Due to the particularity of the pharmaceutical industry, there is uncertainty in sales performance

Dongcheng Biochem: Sodium Fluoride [18F] Injection has passed the drug marketing authorization application

Dongcheng Biochem(002675.SZ)